● Recruiting

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

Condition: Hyperphosphatemia Patients on Hemodialysis · Sponsor: Taisho Pharmaceutical Co., Ltd.

PhasePhase 3

Planned participants100

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

A phase 3, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis

This description comes directly from the study's public registry record.

Talk to the study team

Taisho Pharmaceutical Co., Ltd. Taisho Pharmaceutical Co., Ltd. · 81-3-3985-1118 · shu_chiken@taisho.co.jp

Taisho Director Taisho Director

Always discuss trial participation with your own doctor first.

Locations (1)

Taisho Pharmaceutical Co., Ltd selected site

Tokyo, Japan

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07285291